V-22 Osprey tilt-rotor begins aerial refueling tests
Article Abstract:
Two one-hour aerial refueling flights with the V-22 Osprey tilt-rotor aircraft were conducted where the test pilots logged five "dry plugs" behind a Marine Corps KC-130F tanker and demonstrated the aerial refueling capacity of the aircraft developed by Bell Helicopter Textron and The Boeing Co. for the Marine Corps, Air Force and Navy. The Osprey program that was put on hold after two crashes in 2000, underwent a 18-month review and restructuring and the new test program aims to have six pilots qualified to tank in daylight and at night with the aid of night-vision goggles.
Publication Name: Defense Today
Subject: Business
ISSN:
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
GAO see benefits in larger UCACs from Boeing, Northrop Grumman
Article Abstract:
The author examines a report by the U.S. General Accounting Office on on-going development and military use of unmanned combat aerial vehicles in development at Boeing Co. and Northrop Grumman Corp.
Publication Name: Navy News & Undersea Technology
Subject: Business
ISSN: 8756-1700
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Congress returns to answer defense funding questions. GD CEO says deficits won't curb defense spending. House panel seen adding billions to Bus defense bill
- Abstracts: The role of market orientation in business dyadic relationship: testing an integrator model. Relationship marketing, knowledge management systems and E-commerce operations in small UK accountancy practices
- Abstracts: Factors influencing the magnitude of cartel overcharges: An empirical analysis of food-industry cartels. Modeling coupon values for ready-to-eat breakfast cereals
- Abstracts: Tactical Tomahawk scores another successful test flight. UAVs compete, show varying strengths: no clear winner
- Abstracts: Fingerprinting the circulating repertoire of antibodies from cancer patients. The rollercoaster ride to anti-cancer antibodies